What is this study about redifferentiating medications for thyroid cancer?

This study is collecting information on how redifferentiating medications are used in standard care for radioactive iodine-refractory thyroid cancer. Researchers want to understand patient outcomes and medication tolerance in routine treatment. The study is led by Memorial Sloan Kettering Cancer Center and aims to improve knowledge about these treatments.

Who may be eligible for this thyroid cancer clinical trial?

Adults aged 18 or older with radioactive iodine-refractory thyroid cancer or unlikely to respond to radioactive iodine may be eligible. Participants must be receiving redifferentiation agents as part of regular clinical care and not as part of another clinical trial. This study is open to all genders. Please review eligibility criteria for more details.

Is there any cost to participate in this thyroid cancer clinical trial?

Study-related care, including follow-up visits and data collection, is provided at no cost. However, personal travel or other expenses related to attending visits may vary and might not be covered by the study.

Actively Recruiting

Age: 18Years +

All Genders

ID05733013

Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care A Prospective Data Collection Study

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-27

100

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are collecting information on the use of redifferentiating medications as a standard treatment for patients with radioactive iodine RAI-refractory thyroid cancer. This study is a registry designed to learn more about how these medications are used in routine clinical care for this condition. It is an observational study focused on patients who have thyroid cancer that does not respond well to RAI treatment. Participants will undergo follow-up visits at intervals determined by their usual clinical care. During these visits, researchers will record how well patients tolerate the redifferentiating medications and any adverse events they experience. The study includes patients receiving these agents as part of their regular treatment, both prospectively and retrospectively, but excludes those receiving such agents within other clinical trials. Participants will be monitored for adverse events at every visit over a period of two years. Researchers will collect and review data on medication tolerance and side effects during these follow-up appointments. This ongoing observation aims to provide a clearer picture of outcomes for patients treated with redifferentiation agents in usual care settings.

CONDITIONS

Brief Title

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Patients 18 years or older at time of consent
Diagnosed with radioactive iodine-refractory thyroid cancer or unlikely to respond to radioactive iodine
Receiving redifferentiation agents before planned diagnostic or therapeutic radioactive iodine as part of routine clinical care
Patients who have never received redifferentiation agents outside of a clinical trial or who received them during a clinical trial but now are treated as part of routine care
Patients previously treated with redifferentiation agents in clinical care willing to provide retrospective and prospective data

You will not qualify if you...

Patients receiving redifferentiation agents before radioactive iodine as part of a prospective clinical trial

Research Team

Laura Boucai, MD

Alan Ho, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here